Please assess the completion status of the following clinical trial:

Trial Title: Abuse Liability of Suboxone Versus Subutex

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnostic and Statistical Manual (DSM) IV criteria for heroin dependence~* No major mood, psychotic, or anxiety disorder~* Physically healthy~* Able to perform study procedures~* 21-45 years of age~* Normal body weight~* Current use of i.v. opioids in amounts and/or frequencies that meet or exceed those used in the proposed study (1-2 bags of heroin per occasion at least twice per day)~* Self-administer at least 4 mg i.v. buprenorphine above placebo levels during the dose run up phase~Exclusion Criteria:~* DSM IV criteria for dependence on drugs other than opioids, nicotine or caffeine~* Participants requesting treatment~* Participants on parole or probation~* Pregnancy or lactation~* Birth, miscarriage or abortion within 6 months~* Current or recent history of significant violent behavior~* Current major Axis I psychopathology, other than opioid dependence (e.g., mood disorder with functional impairment or suicide risk, schizophrenia), that might interfere with ability to participate in the study~* aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 3 times the upper limit of normal~* Significant suicide risk~* Current chronic pain~* Sensitivity, allergy, or contraindication to opioids~* Current or recent (past 30 days) physical dependence on or treatment with methadone, buprenorphine, or the buprenorphine/naloxone combination

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Heroin (Type: ACTIVE_COMPARATOR): Heroin 25 mg. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
- Naloxone (Type: ACTIVE_COMPARATOR): Naloxone (NAL) .4 mg. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
- Low Bup Dose (Type: EXPERIMENTAL): Combined dosing groups of (4 mg and 8mg of Buprenorphine) for participants who administered a maximum of 8 mg of Bup during the qualification phase. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
- Low Bup/Nal Dose (Type: EXPERIMENTAL): Combined dosing groups of (4/1 mg and 8/2mg of Buprenorphine + Naloxone) for participants who administered a maximum of 8 mg of Bup during the qualification phase. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
- High Bup Dose (Type: EXPERIMENTAL): Combined dosing groups of (8mg and 16mg of Bup) for participants who administered a maximum of 16 mg of Bup during the qualification phase. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
- High Bup/Nal Dose (Type: EXPERIMENTAL): Combined dosing groups of (8/2mg and 16/4mg of Buprenorphine + Naloxone) for participants who administered a maximum of 16 mg of Bup during the qualification phase. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.
- Placebo (Type: PLACEBO_COMPARATOR): Intravenous placebo (PCB) administration. Administered intravenously, while participants were under 2, 8 and 24 sublingual (SL) Bup maintenance conditions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete